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Abstract Quantum dot is a special kind of nanomaterial
composed of periodic groups of II–VI, III–V or IV–VI
materials. Their high quantum yield, broad absorption with
narrow photoluminescence spectra and high resistance to
photobleaching, make them become a promising labeling
substance in biological analysis. Here, we report a quick
and parallel analytical method based on quantum dots for
ToRCH-related antibodies including Toxoplasma gondii,
Rubella virus, Cytomegalovirus and Herpes simplex virus
type 1 (HSV1) and 2 (HSV2). Firstly, we fabricated the
microarrays with the ﬁve kinds of ToRCH-related antigens
and used CdTe quantum dots to label secondary antibody
and then analyzed 100 specimens of randomly selected
clinical sera from obstetric outpatients. The currently pre-
valent enzyme-linked immunosorbent assay (ELISA) kits
were considered as ‘‘golden standard’’ for comparison. The
results show that the quantum dots labeling-based ToRCH
microarrays have comparable sensitivity and speciﬁcity
with ELISA. Besides, the microarrays hold distinct
advantages over ELISA test format in detection time, cost,
operation and signal stability. Validated by the clinical
assay, our quantum dots-based ToRCH microarrays have
great potential in the detection of ToRCH-related
pathogens.
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Introduction
Microarrays (biochips) have been an essential part of the
biomarker research workﬂow for over 10 years. So far,
deoxyribonucleic acid (DNA) microarrays are mainly used
for gene expression proﬁle analysis and single nucleotide
polymorphism (SNP) detection to better classify and detect
diseases [1–4]. The protein microarrays are mainly applied
to disease-associated serological biomarkers detection, new
drug development and biomarker molecules screening.
These advantages enable microarrays to become a high-
throughput tool applied in the parallel analysis, which can
be used to monitor simultaneously the levels of a multitude
of target molecules in a single specimen. In many recent
reports, the protein microarray approaches with immobi-
lized pathogen-related antigens were used for the parallel
detection of relative antibodies in sera [5–8]. Based on the
principles of antigen–antibody interaction, almost any
combination of pathogen-related antigens with speciﬁc
purposes can be immobilized onto the surface of micro-
array substrates for the diagnosis of corresponding dis-
eases. However, for some reasons, the application of this
technology into diagnostics and clinical practice has
developed very slowly. In clinical diagnosis, there is an
increasing need for simple and sensitive analytical method
for antigen or antibody detection. One of the solutions is to
seek a kind of sensitive and stable labeling substance. Take
traditional colloidal gold as an example, it has been
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diagnosis of diseases [9, 10], but in fact, the sensitivity of
traditional gold nanoparticles-based diagnosis method
cannot fully meet the requirement of the rapid and sensitive
diagnosis. As nanotechnology advances fast, the nanoma-
terials bring a new opportunity to the development of
simple and sensitive diagnostic tools [11–13].
Quantum dots (QDs), one of those promising nanoma-
terials, have been subjected to intensive investigations
because of their unique photoluminescent properties and
potential applications. So far, several methods have been
developed to synthesize water-soluble quantum dots for use
in biologically relevant studies [14]. According to previous
reports, quantum dots have been successfully used in cel-
lular imaging [15], immunoassays [16], DNA hybridization
[17] and optical bar-coding [18]. Moreover, quantum dots
also have been used to study the interaction between pro-
tein molecules or detect the dynamic course of signal
transduction in live cells by ﬂuorescence resonance energy
transfer (FRET) [19]. These synthesized quantum dots
have signiﬁcant advantages over traditional ﬂuorescent
dyes, including better stability, stronger ﬂuorescent inten-
sity and size-tuning colors, which are adjusted by con-
trolling the size of quantum dots [20]. Therefore, quantum
dots provide a new functional platform for bioanalytical
sciences and biomedical engineering.
In the obstetrics, the ToRCH is referred as ﬁve patho-
gens including Toxoplasmosis, Rubella, Cytomegalovirus
and Herpes simplex virus type 1 and 2. If ToRCH-related
pathogens infect pregnant women, they will cause severe
fetal anomalies or even fetal loss [21, 22]. For this reason,
it is of great practical signiﬁcance to establish a simple,
sensitive detection method for ToRCH pathogens. Here, we
report a quick and parallel analytical method based on
quantum dots labeling for ToRCH-related antibodies. In
our work, we fabricated the microarrays with the ﬁve
ToRCH-related antigens and screened 100 specimens of
randomly selected clinical sera from outpatients along with
quantum dots-labeled secondary antibody. At the same
time, we selected commercially available enzyme-linked
immunosorbent assay (ELISA) kits to detect these speci-
mens as ‘‘golden standard’’; the results were compared with
that of quantum dots label-based ToRCH microarrays.
Materials and Methods
Materials
Thioglycolic acid (TGA), sodium borohydride and carbo-
diimide hydrochloride (EDC) are purchased from Sigma
(Sigma, USA) and were used without further treatment or
puriﬁcation. All synthetic preparations and measurements
were carried out in Millipore water as solvent with 18 MX/
cm or less. All other analytically puriﬁed reagents were
purchased domestically. The nitrocellulose membrane with
a pore size of 0.45 lm was purchased from Amersham (GE
healthcare, USA). The macromolecular bibulous materials
and the outer plastic shells were customized from Yi li
Packaging Co Ltd. Human immunoglobulin G (IgG) and
sheep-anti-human secondary antibodies, as well as bovine
serum albumin (BSA), were purchased from Sigma
(Sigma, USA). Five ToRCH-related antigens (Toxoplas-
mosis, Rubella, Cytomegalovirus and Herpes simplex virus
type 1 and 2) were purchased from Microbix Biosystems
(Canada). Phosphate-buffered saline (PBS) (137 mM
NaCl, 2.7 mM KCl, 1.4 mM KH2PO4 and 25 mM
Na2HPO4, pH 7.4, 1% glycerol) and PBST buffers (PBS
buffer with 0.05% Tween-20) were used. The ELISA kits
for comparison were purchased from Zeus (Zeus, USA).
Collection of Samples
Negative and positive control sera of the ﬁve ToRCH
antibodies were from Fourth Military Medical University
and were kept in our laboratory, all of which were vali-
dated jointly by two commercial ELISA kits (Viron and
Diesse). The validation assays were performed according
to the manufacturer’s instructions. About 100 random sera
were collected from outpatients at the gynecological
department of Tangdu Hospital and frozen at -20 C. This
study was performed according to the Helsinki Declaration
and was approved by the Ethical Committee of Fourth
Military Medical University.
The Preparation of TGA-Capped QDs
QDs were prepared according to our previous report [13].
The concrete steps are as follows: 5 mM of CdCl2 2.5 H2O
was dissolved in 110 mL of water, and 12 mM of TGA
was added under stirring; this was followed by adjusting
the pH to 11 by dropwise addition of 1 M NaOH solution.
The solution was placed in a three-necked ﬂask deaerated
by N2 bubbling for 30 min. Under stirring, 2.5 mM of
oxygen-free NaHTe solution, which was freshly prepared
from tellurium powder and NaBH4 (molar rate of 1:2) in
water at 0 C, was injected into the three-necked ﬂask. The
resultant mixtures were reﬂuxed at 100 C for 4 h. By this
means, the 2.5 nm diameter TGA-capped CdTe QDs
emitted with a maximum wavelength around 545 nm were
obtained.
The Characterization of QDs
Photoluminescence (PL) spectra were used to characterize
the ﬂuorescent properties of QDs; they were measured in
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1231 cm quartz in air at room temperature using a Perkin
Elmer LS 55 spectroﬂuorimeter. The size determination of
QDs was performed using a transmission electron micro-
scope (TEM, JEM2010, at 200 kV).
The Conjugation of Sheep-Anti-Human Secondary
Antibodies with QDs
After the synthesis of QDs, 50 lL of 2 mg/mL QDs and
400 lLof2 mg/mLsheep-anti-humansecondaryantibodies
were mixed, and then 300 lL of 1-ethyl-3-(3-dimethyl-
aminopropyl)-carbodiimide EDC (44 mM in borate buffer)
were added and blended by vortex. The resulting solution
was allowed to react at room temperature for 1 h with
continuous mixing and then at 4 C for 24 h. The overnight
QDs-labeled secondary antibodies were centrifuged at
12,000 rpm for 20 min, and the supernatant was discarded.
PBST was used to resuspend and wash QDs-labeled sec-
ondary antibodies by centrifugation at 12,000 rpm for three
times. Finally, the QDs-labeled secondary antibodies were
dispersed in PBST and kept at 4 C until use.
Preparation of Microarrays
The rationale of QDs-based microarray is shown in Fig. 1.
Brieﬂy, the antigens of Toxoplasma gondii, Rubella virus,
Cytomegalovirus and Herpes simplex viruses were printed
on a nitrocellulose membrane with a pore size of 0.45 lm
at a concentration of 1 mg/mL by computer-controlled,
high-speed robotics. Each pin of the robotics was estimated
to transfer about 1 nL of antigen solution to the nitrocel-
lulose membrane. The microarray consisted of a 4 9 4
matrix, including the ﬁve pathogen-related antigens and
human IgG positive control in duplicate (Fig. 2). Bovine
albumin was printed on the microarray as blanking control
indicating possible cross-contamination between pins.
Following printing, the microarrays were blocked with
PBS containing 10 mg/mL bovine albumin for 1 h at 37 C
and then assembled with macromolecular bibulous mate-
rials and plastic outer shells. The ﬁnished microarrays were
stored at 4 C until further usage.
Detection of Clinical Specimens
The procedure for testing with microarray is as follows:
ﬁrstly, 100 lL of PBST was added onto the microarray to
wet it. After PBST inﬁltrated through the nitrocellulose
membrane, 200 lL of serum was added, then the mem-
brane was washed for three times with PBST in order to
remove unbound antibodies. About 300 lL of QDs-labeled
secondary antibody solution was added subsequently. The
membrane was washed three times with PBST again. The
portable ultraviolet lamp was used to excite QDs-labeled
secondary antibodies on microarray, and the test result was
determined by naked eyes. The existence of QDs ﬂuores-
cence on the spot immobilizing corresponding antigens
was determined as positive specimen and vice versa. In our
experiment, 10 negative and positive control sera were
used to validate ToRCH microarrays. About 100 random
sera were tested for ToRCH-related antibodies with our
microarrays and commercial ELISA kit from ZEUS Sci-
entiﬁc, Inc. The performance of ELISA was based on the
manufacturer’s instructions. The assay results were ana-
lyzed with Statistics Package for Social Sciences (SPSS)
software. The sensitivity and speciﬁcity of our microarray
are calculated by following formulas:
Sentivity ¼
Truepositive
Truepositve þ Falsenegative
Specificity ¼
Truenegative
Truenegative þ Falsepositive
:
Fig. 1 The rationale of
QDs-based microarray
Fig. 2 Schematic representation of microarray
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123Results and Discussion
The diameter and narrow size distribution of as-prepared
CdTe nanocrystals synthesized in this work were deter-
mined by TEM. A representative example was presented in
Fig. 3. The mean particle diameter is 2.5 nm. The ﬂuo-
rescence spectra and images of QDs before and after the
coupling with sheep-anti-human secondary antibodies
under UV irradiation are shown in Fig. 4. According to our
results, the QDs have strong ﬂuorescence, and the maximum
ﬂuorescence wavelength for CdTe was at approximately
545 nm. Besides, green-yellow ﬂuorescence could be
observed under a portable UV lamp. However, the blue
shift occurred after the coupling of QDs with sheep-
anti-human secondary antibodies, and the yellow ﬂuores-
cence of QDs turned green. The probable reason is that the
carboxyl group on the surface of QDs was covalently
combined with the amino group of sheep-anti-human IgG,
reduced the surface charge of QDs, decreased the polari-
zation rate of the surrounding molecules and then reduced
the Stokes displacement, ﬁnally resulting in a blue shift in
the emission spectra [23]. Meanwhile, the full width at half
maximum (FWHM) of the QDs and QDs-labeled antibody
remained constant, which meant no aggregation happened
to the QDs in the coupling process.
We randomly selected 20 microarrays from as-prepared
microarrays and validated them with control sera; the
random detection results were consistent with corre-
sponding control sera (Fig. 5). Afterward, 100 random sera
from the outpatients were analyzed with our microarrays
and the commercial ELISA kits, respectively. The assay
results were analyzed using SPSS software. The test results
showed that the infectious rates of ToRCH-related agents
in these specimens collected from the gynecological
department were 83% for Toxoplasmosis, 91% for Rubella,
82% for Cytomegalovirus, 73% for Herpes simplex virus
type 1 and 18% for Herpes simplex virus type 2, which
were rather close to those of commercial ELISA kits.
Moreover, there is no signiﬁcant difference between the
two methods. Compared with the ELISA kits, both sensi-
tivity and speciﬁcity of the microarrays exceeded 85%
(Table 1).
The prenatal screening of ToRCH-related pathogens is
of great signiﬁcance in eugenics. Up to the present, the
ELISA test format has been playing an important role in
the ﬁrst-line method of diagnosis for current, recent or past
infection of those ToRCH-related pathogens [24, 25]. The
inherent methodological limitation of ELISA test format
makes it a time-consuming and tangled laboratory diag-
nostic format. Especially, during screening for multiple
targets from the same analyte, the repetitious procedures
multiple the laboratorial workloads undoubtedly. Although
there have been many automatic immunowashers that were
commercially developed in order to decrease laboratorial
workloads and increase test throughput, they still could not
resolve the problem of inﬂexibility and single test time. In
this regard, the combination of ﬁltration assay with QDs-
labeled probe can offer great advantages over enzyme-
based and other kinds of ﬂuorescence-based analytical
formats. According to our experiments, compared with
ELISA format, the QDs-based microarray possesses these
unsurpassable advantages including parallel analysis, test
time, test cost, signal stability and instrument requirement.
The currently available ELISA and ﬂuorescent immuno-
logical test suffer from laborious repeated procedures,
while our microarrays allow parallel analysis of multiple
target molecules. In addition, each ELISA or ﬂuorescent
immunological test will cost a skilled laboratory assistant
2–3.5 h, while our microarray tests only require
Fig. 3 TEM image of prepared QDs
Fig. 4 Fluorescence spectra of QDs solution before and after labeling
with goat-anti-human IgG (inset: images of QDs before and after the
coupling with second antibodies under UV irradiation)
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123approximately 10–20 min through four simple steps.
Besides, each spot of detection only needs 10–20 ng anti-
gens, whereas ELISA format needs 100–200 ng antigens
for coating. Moreover, the signal stability of QDs probe
is strong and lasting. As reported previously, dihydroli-
poic acid (DHLA)-capped cadmium selenide–zinc sulﬁde
(CdSe–ZnS) QDs showed no loss in intensity after 14 h
and were nearly 100 times as stable as, and also 20 times as
bright as Rhodamine 6G [19]. Last but not least, the
identiﬁcation of the microarray results does not need any
special instrument, whereas the ELISA method needs an
enzyme immune analyzer, and other ﬂuorescent immuno-
logical tests need an expensive ﬂuorescent scanner or
detector.
Conclusions
In this paper, we prepared QDs-based protein microarray to
simultaneously detect ToRCH-related antibodies in sera.
The rationale of detection is based on immunoﬁltration
assay and QDs-labeled probes. So far, the advent of protein
microarrays has made ﬂexible, high-throughput screening
of multiple targets in different analytes come true. How-
ever, only an easy-to-use and cheap solution is much more
suitable for the popularization of this advanced detection
format. Our microarrays have shown the unique advantages
in aspects of parallelism, cost, signal stability and usability,
overcoming most limitations of the current prevalent
ELISA test format. Furthermore, compared with other
ﬂuorescent immunological microarrays based on glass or
silicon chip, our microarrays are much rapider in detection
time, much easier in operation, much more stable and
stronger in signal. Validated by clinical application, there is
no signiﬁcant difference between the current golden stan-
dard ELISA and our microarray in detecting ToRCH
infections. Although the results are promising, there is still
a need to develop a kind of miniaturized ultraviolet reader
to objectively differentiate and sensitively detect clinical
specimens in practical application. However, without
expensive laser excitation source and confocal scanner, this
kind of reader will be much cheaper and portable. In
Fig. 5 The microarray results
with corresponding control sera
(a negative serum; b positive
control serum of
Toxoplasmosis; c positive
control serum of
Cytomegalovirus; d positive
control serum of Rubella virus;
e positive control serum of
Herpes simplex virus type 1;
f positive control serum of
Herpes simplex virus type 2)
Table 1 Comparison of results between QDs-based microarray and ELISA
ELISA ELISA ELISA ELISA ELISA
TOX
?
TOX
–
Sum RV
?
RV
–
Sum CMV
?
CMV
–
Sum HSV I
?
HSV I
–
Sum HSV II
?
HSVII
–
Sum
? 81 2 83 90 1 91 80 2 82 71 2 73 14 4 18
– 1 16 17 1 8 9 2 16 18 2 25 27 2 80 82
Sum 82 18 100 91 9 100 82 18 100 73 27 100 16 84 100
v
2 0 0.5 0.25 0.25 0.17
p \0.05 \0.05 \0.05 \0.05 \0.05
p\0.05, there was no signiﬁcant difference between the two methods
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123conclusion, our microarray has a high potential in mass
prenatal on-site screening or epidemiological research.
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